Amyris seals $50M deal with DSM Nutritional Products

In California, Amyris announced the closing of a strategic transaction with DSM Nutritional Products Ltd., the first of three anticipated transactions management described during its recent virtual investor mini-series event, held on December 15, 2020.

Under the terms of the agreement Amyris is licensing to DSM rights to assume the supply of Farnesene to Givaudan for the production and sale of a single specialty ingredient. The transaction is valued at $50 million, with $30 million payable by December 30, 2020, $10 million payable in the first quarter of 2021, and the remainder in milestone payments thereafter.

Amyris was advised by BNP Paribas on the transaction.